Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomised, Double-blind, Placebo-controlled, Proof-of-mechanism Phase 2 Trial Investigating the Effect of Quinagolide Extended-release Vaginal Ring on Reduction of Lesions Assessed by High-resolution Magnetic Resonance Imaging in Women With Endometrioma, Deep Infiltrating Endometriosis, and/or Adenomyosis

Trial Profile

A Randomised, Double-blind, Placebo-controlled, Proof-of-mechanism Phase 2 Trial Investigating the Effect of Quinagolide Extended-release Vaginal Ring on Reduction of Lesions Assessed by High-resolution Magnetic Resonance Imaging in Women With Endometrioma, Deep Infiltrating Endometriosis, and/or Adenomyosis

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 13 Feb 2019

At a glance

  • Drugs Quinagolide (Primary)
  • Indications Adenomyosis; Endometriosis
  • Focus Therapeutic Use
  • Acronyms QLARITY
  • Sponsors Ferring Pharmaceuticals
  • Most Recent Events

    • 04 Feb 2019 Planned End Date changed from 1 Nov 2020 to 1 Dec 2020.
    • 04 Feb 2019 Planned primary completion date changed from 5 Oct 2020 to 1 Nov 2020.
    • 19 Dec 2018 Planned initiation date changed from 1 Jan 2019 to 1 Feb 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top